Indivior Pharmaceuticals, Inc. (INDV)
NASDAQ
Closed
Aug 24, 2026
Day's Range
35.4052 wk Range
22.22Overview - INDV - Indivior Pharmaceuticals, Inc.
Key Statistics
Valuation
Enterprise Value
4.63B
P/E (Trailing)
‪13.21‬
P/E (Forward)
‪7.55‬
PEG Ratio
‪0.02‬
Price / Sales (TTM)
‪3.26‬
Price / Book
‪-20.99‬
EV / EBITDA
‪8.05‬
Profitability
Gross Margin
‪85.42%‬
Profit Margin
‪26.74%‬
Operating Margin
‪46.93%‬
Return on Assets
‪26.39%‬
Return on Equity
‪-212.12%‬
Ownership
Shares Outstanding
118.00M
Float
116.03M
Short % of Shares Outstanding
‪10.95%‬
Held by Insiders
‪2.01%‬
Held by Institutions
‪98.93%‬
Price stats
Beta
‪1.13‬
50-Day Avg
‪39.56‬
200-Day Avg
‪35.41‬
Dividends
Payout Ratio
‪0.00%‬
Analyst Consensus
4 analysts
Average price target
‪$ 49.00‬Shariah Compliance
Report Date: Feb 20, 2025
Screened by Zoya using the AAOIFI methodology.
Market Cap - INDV - Indivior Pharmaceuticals, Inc.
Peers - INDV - Indivior Pharmaceuticals, Inc.
Peer Comparison
Compared with companies in Drug Manufacturers - Specialty & Generic listed on NASDAQ.
- INDVNASDAQIndivior Pharmaceuticals, Inc.4.35BMarket Cap+34.88%52-week change13.22P/E (Trailing)‪26.74%‬Profit Margin
- NBIXNASDAQNeurocrine Biosciences Inc.15.50BMarket Cap+12.18%52-week change22.34P/E (Trailing)‪20.91%‬Profit Margin
- ALALKSNASDAQAlkermes plc8.10BMarket Cap+40.00%52-week change127.37P/E (Trailing)‪3.96%‬Profit Margin
- LNTHNASDAQLantheus Holdings, Inc.6.52BMarket Cap+43.82%52-week change23.92P/E (Trailing)‪17.69%‬Profit Margin
- AMRXNASDAQAmneal Pharmaceuticals Inc.6.23BMarket Cap+48.19%52-week change37.60P/E (Trailing)‪5.04%‬Profit Margin
- KNKNSANASDAQKiniksa Pharmaceuticals International, plc6.16BMarket Cap+58.19%52-week change79.83P/E (Trailing)‪9.59%‬Profit Margin
- ALMNASDAQAlmonty Industries Inc.5.33BMarket Cap+76.82%52-week change84.14P/E (Trailing)‪125.23%‬Profit Margin
Profile Summary - INDV - Indivior Pharmaceuticals, Inc.
About
Indivior Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing, manufacturing, and commercializing buprenorphine-based prescription medications for treating opioid use disorder and related substance dependence. Its core products include SUBLOCADE, a once-monthly extended-release…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Shariah compliance data provided by Zoya. Charting by TradingView.
Last updated:
